Concepedia

Publication | Open Access

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells

DOIFull Paper Access

81

Citations

28

References

2018

Year

Pranav Gupta, Yunkai Zhang, Xiaoyu Zhang, Yi‐Jun Wang, Kimberly Lu, Timothy L. Hall, Richard Peng, Dong‐Hua Yang, Ni Xie, Zhe‐Sheng Chen
Cellular Physiology and Biochemistry

Abstract

Voruciclib is currently a phase I clinical trial drug. Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.

References

YearCitations

Page 1